Kalaris Therapeutics, Inc. (KLRS) bonds
KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.43−0.03 (-2.05%)
Close on Nov 17, 2026Market cap $34.04MP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Kalaris Therapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Kalaris Therapeutics's 10-Q for the period ended Jun 30, 2026
| Issue | Coupon | Amount issued | Carrying value |
|---|---|---|---|
| 2024 Convertible Promissory Note Convertible at $6 a share | 10.00% | $10.00M | $0 |
| 2025 Bridge Notes | – | $3.75M | – |
| January 2025 AlloVir Convertible Promissory Note Convertible | – | $3.75M | – |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn |
|---|---|---|
| 2024 Bridge Notes | $15.00M | $0 |
See a number that looks wrong?